Biopharmx Corp (NYSEAMERICAN:BPMX)’s share price traded down 5.9% on Wednesday . The company traded as low as $0.14 and last traded at $0.16. 8,871,081 shares traded hands during mid-day trading, a decline of 21% from the average session volume of 11,232,039 shares. The stock had previously closed at $0.17.

Separately, Maxim Group reissued a “buy” rating and issued a $1.50 price target on shares of Biopharmx in a research note on Friday, December 8th.

The company has a market capitalization of $21.46, a PE ratio of -0.59 and a beta of 1.40.

Biopharmx (NYSEAMERICAN:BPMX) last announced its earnings results on Thursday, December 7th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.05).

In other Biopharmx news, Director Stephen Morlock acquired 330,000 shares of Biopharmx stock in a transaction dated Friday, November 24th. The stock was bought at an average cost of $0.15 per share, with a total value of $49,500.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

A hedge fund recently bought a new stake in Biopharmx stock. Armistice Capital LLC bought a new stake in Biopharmx Corp (NYSEAMERICAN:BPMX) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 3,470,000 shares of the biotechnology company’s stock, valued at approximately $382,000. Armistice Capital LLC owned approximately 2.72% of Biopharmx at the end of the most recent quarter.

WARNING: “Biopharmx (BPMX) Shares Down 5.9%” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this piece can be read at https://www.thecerbatgem.com/2018/02/14/biopharmx-bpmx-shares-down-5-9.html.

About Biopharmx

BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women’s health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia.

Receive News & Ratings for Biopharmx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx and related companies with MarketBeat.com's FREE daily email newsletter.